Nat Lenzo

3.6k total citations · 1 hit paper
44 papers, 1.7k citations indexed

About

Nat Lenzo is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Epidemiology. According to data from OpenAlex, Nat Lenzo has authored 44 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 24 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Epidemiology. Recurrent topics in Nat Lenzo's work include Radiopharmaceutical Chemistry and Applications (19 papers), Prostate Cancer Treatment and Research (16 papers) and Medical Imaging Techniques and Applications (5 papers). Nat Lenzo is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (19 papers), Prostate Cancer Treatment and Research (16 papers) and Medical Imaging Techniques and Applications (5 papers). Nat Lenzo collaborates with scholars based in Australia, United States and Austria. Nat Lenzo's co-authors include Danielle Meyrick, Ralph N. Martins, Kevin Taddei, Jonathan K. Foster, Mina John, James Flexman, Martyn A. French, E. McKinnon, S. Mallal and J. Harvey Turner and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Neuroscience & Biobehavioral Reviews.

In The Last Decade

Nat Lenzo

42 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease

2009 627 citations Kathryn A. Ellis, Ashley I. Bush et al. International Psychogeriatrics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nat Lenzo Australia	19	465	410	407	340	332	44	1.7k
Raffaele Giubbini Italy	28	746 1.6×	152 0.4×	338 0.8×	218 0.6×	139 0.4×	98	2.3k
Juli Alonso Spain	33	814 1.8×	268 0.7×	330 0.8×	161 0.5×	876 2.6×	63	2.9k
Nicola Morelli Italy	18	319 0.7×	278 0.7×	183 0.4×	163 0.5×	278 0.8×	115	1.4k
Panayiotis Mitsias United States	29	300 0.6×	352 0.9×	592 1.5×	106 0.3×	828 2.5×	100	2.7k
Richard B. Noto United States	23	426 0.9×	220 0.5×	228 0.6×	95 0.3×	266 0.8×	68	1.7k
Tadamasa Yoshitake Japan	19	310 0.7×	429 1.0×	526 1.3×	350 1.0×	185 0.6×	97	1.8k
Staffan Eriksson Sweden	24	266 0.6×	329 0.8×	133 0.3×	147 0.4×	226 0.7×	64	2.7k
Ashkan Shoamanesh Canada	29	197 0.4×	315 0.8×	347 0.9×	452 1.3×	1.6k 4.8×	135	3.3k
Usha B. Tedrow United States	44	438 0.9×	89 0.2×	283 0.7×	227 0.7×	367 1.1×	212	6.7k
Luigina Guasti Italy	31	274 0.6×	84 0.2×	249 0.6×	464 1.4×	396 1.2×	145	3.1k

Countries citing papers authored by Nat Lenzo

Since Specialization

Citations

This map shows the geographic impact of Nat Lenzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nat Lenzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nat Lenzo more than expected).

Fields of papers citing papers by Nat Lenzo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nat Lenzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nat Lenzo. The network helps show where Nat Lenzo may publish in the future.

Co-authorship network of co-authors of Nat Lenzo

This figure shows the co-authorship network connecting the top 25 collaborators of Nat Lenzo. A scholar is included among the top collaborators of Nat Lenzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nat Lenzo. Nat Lenzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yanagisawa, Takafumi, Akihiro Matsukawa, Paweł Rajwa, et al.. (2025). Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases. 1 indexed citations

Yanagisawa, Takafumi, Atsuya Okada, Hidetoshi Kuruma, et al.. (2025). Comparison of diagnostic performance between manual diagnosis following PROMISE V2 and aPROMISE utilizing Ga/F-PSMA PET/CT. Annals of Nuclear Medicine. 39(11). 1278–1286.

Tagawa, Scott T., et al.. (2025). ProstACT GLOBAL: A phase 3 study of ¹⁷⁷ Lu-rosopatamab (TLX591) with and without the best standard of care for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.. Journal of Clinical Oncology. 43(5_suppl).

Nguyen, Hanh V., et al.. (2024). Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes. Molecular Diagnosis & Therapy. 28(3). 291–299. 6 indexed citations

Sartor, Oliver, Scott T. Tagawa, Nat Lenzo, David Cade, & Neeraj Agarwal. (2024). ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.. Journal of Clinical Oncology. 42(16_suppl). TPS5115–TPS5115. 1 indexed citations

Viswambaram, Pravin, Elizabeth Liow, Nat Lenzo, et al.. (2022). ⁸⁹ Zirconium-labelled girentuximab ( ⁸⁹ Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma. BMJ Open. 12(4). e060478–e060478. 10 indexed citations

Kesavan, Murali, et al.. (2021). Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients. Diagnostics. 11(3). 515–515. 4 indexed citations

Falzone, Nadia, et al.. (2021). Combining External Beam Radiation and Radionuclide Therapies: Rationale, Radiobiology, Results and Roadblocks. Clinical Oncology. 33(11). 735–743. 16 indexed citations

Meyrick, Danielle, et al.. (2021). Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer. Targeted Oncology. 16(3). 369–380. 32 indexed citations

10.

Nicolas, Guillaume, C. Ansquer, Nat Lenzo, et al.. (2020). 1160O An international open-label study on safety and efficacy of 177Lu-satoreotide tetraxetan in somatostatin receptor positive neuroendocrine tumours (NETs): An interim analysis. Annals of Oncology. 31. S771–S771. 8 indexed citations

11.

Kesavan, Murali, et al.. (2018). Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice. Cancer Biotherapy and Radiopharmaceuticals. 33(7). 274–281. 21 indexed citations

12.

Meyrick, Danielle, et al.. (2017). The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer. Nuclear Medicine Communications. 38(11). 956–963. 27 indexed citations

13.

Bird, Sabine, Hamid R. Sohrabi, Michael Weinborn, et al.. (2016). Cerebral amyloid-β accumulation and deposition following traumatic brain injury—A narrative review and meta-analysis of animal studies. Neuroscience & Biobehavioral Reviews. 64. 215–228. 39 indexed citations

14.

Lenzo, Nat, et al.. (2014). Carotid Artery Ultrasonographic Assessment in Patients from the Fremantle Diabetes Study Phase II with Carotid Bruits Detected by Electronic Auscultation. Diabetes Technology & Therapeutics. 16(9). 604–610. 4 indexed citations

15.

Ellis, Kathryn A., Ashley I. Bush, David Darby, et al.. (2009). The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. International Psychogeriatrics. 21(4). 672–687. 627 indexed citations breakdown →

16.

Potter, Kathleen N., Nat Lenzo, John W. Eikelboom, et al.. (2009). Effect of Long-Term Homocysteine Reduction with B Vitamins on Arterial Wall Inflammation Assessed by Fluorodeoxyglucose Positron Emission Tomography: A Randomised Double-Blind, Placebo-Controlled Trial. Cerebrovascular Diseases. 27(3). 259–265. 28 indexed citations

17.

Almeida, Osvaldo P., Griselda J. Garrido, Nicola T. Lautenschlager, et al.. (2008). Coronary heart disease is associated with regional grey matter volume loss: implications for cognitive function and behaviour. Internal Medicine Journal. 38(7). 599–606. 23 indexed citations

18.

Lenzo, Nat, et al.. (2005). Pseudolymphoma Syndrome: Findings on a Gallium-67 Citrate Scan. Clinical Nuclear Medicine. 31(1). 16–17. 1 indexed citations

19.

Lenzo, Nat & George Garas. (1998). Biliary stent migration with colonic diverticular perforation. Gastrointestinal Endoscopy. 47(6). 543–544. 40 indexed citations

20.

Lenzo, Nat, Ian Martins, Bok‐Cheng Mortimer, & Trevor G. Redgrave. (1988). Effects of phospholipid composition on the metabolism of triacylglycerol, cholesteryl ester and phosphatidylcholine from lipid emulsions injected intravenously in rats. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 960(1). 111–118. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact